Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

OVERVIEW

The use of immunotherapies promises improved outcomes for cancer patients. However, their mechanisms of action (MOAs), response patterns and adverse event (AE) management strategies differ greatly from traditional chemotherapies and even the newer targeted therapies. Cytotoxic chemotherapy, which has long been a mainstay of cancer treatment, indiscriminately attacks all dividing cells. In contrast to this, targeted therapies interfere with specific pathways needed for tumor growth. Immunotherapies, which represent a novel type of targeted therapy, are the result of an immune response generated in the patient. Although active immunotherapeutics were initially approved for melanoma, their roles have been expanded to include treatment of non-small cell lung cancer (NSCLC).

The survival benefits of new and emerging immunotherapies are accompanied by high drug costs, making formulary decisions complex. As these treatments are relatively new, long-term data is not available, leading to questions regarding the durability of response. Other questions affecting payers and contributing to formulary decisions include the usefulness of biomarkers to match patients to immunotherapies, combined use of immunotherapy with other classes of drugs or other immunotherapies, the use of immunotherapies in patients with comorbidities or advanced age, the effects of therapy on patient-reported quality of life, and the limited comparative effectiveness data on available immunotherapies.

This archived symposium will present the most up-to-date information on the use of immunotherapies in melanoma and NSCLC, their unique MOAs, response patterns and AE management strategies. Oncology pharmacist experts will address issues and challenges in incorporating these therapies into clinical practice to positively impact patient outcomes.

GOAL

The goal of this activity is to enhance managed care and specialty pharmacists' understanding of the evolving science, response assessment, and adverse event management regarding immunotherapies in treating patients with NSCLC and melanoma.

TARGET AUDIENCE

This activity is designed for managed care and specialty pharmacists. No prerequisites required.

LEARNING OBJECTIVES

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

• EVALUATE the efficacy and safety of immunotherapy as part of melanoma and NSCLC treatment paradigms.
• RECOGNIZE unique disease response patterns and adverse event management associated with immunotherapy treatment.
• DESCRIBE pharmacy-driven management strategies to optimize treatment plans for melanoma and NSCLC.

CREDIT DESIGNATION STATEMENT

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument  with a score of at least 70%. UAN:  0064-0000-16-224-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Published: December, 31, 2016
Expires: December, 31, 2017

Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes

HOW TO EARN CREDIT

Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES

As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Participating Faculty reported the following:

PARTICIPATING FACULTY

Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
Pharmacy Practice and Science Department
College of Pharmacy
University of Kentucky
Lexington, Kentucky

Dr Adams reports serving on the advisory board for Teva.

Patrick Medina, PharmD, BCOP
Professor of Medicine
Hematology/Oncology
Director of Pharmacy
Stephenson Cancer Center
Oklahoma City, Oklahoma

Dr Medina reports having no relevant financial or advisory relationships with corporate organizations related to this activity

OFF-LABEL PRODUCT DISCUSSION

In accordance with ACPE Criteria for Quality, the audience is advised that discussions in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices, including, but not limited to, the following:

1. Pembrolizumab use in PD-L1 negative tumors
2. Nivolumab and Ipilimumab combination therapy in NSCLC
3. Atezolizumab use in NSCLC
4. Pembrolizumab as first-line therapy for advanced NSCLC

DISCLAIMER STATEMENT

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

ACTIVITY

The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5

TABLE OF CONTENTS

Imunotherapies in Solid Tumors
Val R. Adams, PharmD, FCCP, BCOP

Overview of NSCLC Treatment with Immunotherapies
Val R. Adams, PharmD, FCCP, BCOP

Overview of Melanoma Treatment with Immunotherapies
Patrick Medina, PharmD, BCOP

Pharmacist Role
Patrick Medina, PharmD, BCOP

What you are about to see is a previously recorded live meeting. Please note that only "home study" credit will be awarded for participating in this archived presentation.

No "live" credits are available.